Pluvicto FY26
Ended Awarded Last action
- Contract number
- 36C26126F0017
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,614,171
Award facts
- Contract value 99% obligated
- $1,630,147.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $617,297 | |
| Original award | $996,874 |
About this award
Novartis Pharmaceuticals Corporation received a delivery order award from Veterans Integrated Service Network 21 (VISN 21) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer treatment. The delivery order, awarded October 1, 2025, carries a ceiling value of $1.63M and a firm fixed-price structure under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has no small business set-aside designation, allowing Novartis to compete directly as a large pharmaceutical manufacturer. The ultimate completion date is set for September 30, 2026, with performance taking place at Novartis' East Hanover, New Jersey facility.
This delivery order is issued under a larger single-award Blanket Purchase Agreement valued at $7.48M that VISN 10 awarded to Novartis on October 1, 2025, for PLUVICTO procurement extending through September 30, 2030. The underlying vehicle establishes a framework for the Department of Veterans Affairs to procure this specialized oncology radiopharmaceutical across multiple Veterans Integrated Service Networks to support cancer treatment programs within the federal healthcare system.
Quick answers
Who was awarded contract 36C26126F0017?
36C26126F0017 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 1, 2025.
How much is contract 36C26126F0017 worth?
The government has obligated $1,614,171 on 36C26126F0017. Its current value, with exercised options, is $1,630,148.
Is contract 36C26126F0017 an order under another contract?
Yes. 36C26126F0017 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126F0017 competed?
The extent of competition for 36C26126F0017 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award